{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T09:44:43Z","timestamp":1784454283194,"version":"3.55.0"},"reference-count":48,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Major Project","award":["2017ZX0931057"],"award-info":[{"award-number":["2017ZX0931057"]}]},{"name":"National Science and Technology Major Project","award":["BE2019738"],"award-info":[{"award-number":["BE2019738"]}]},{"name":"National Science and Technology Major Project","award":["2023YFF0723400"],"award-info":[{"award-number":["2023YFF0723400"]}]},{"name":"National Science and Technology Major Project","award":["BM2019004"],"award-info":[{"award-number":["BM2019004"]}]},{"name":"Jiangsu key R&amp;D plan","award":["2017ZX0931057"],"award-info":[{"award-number":["2017ZX0931057"]}]},{"name":"Jiangsu key R&amp;D plan","award":["BE2019738"],"award-info":[{"award-number":["BE2019738"]}]},{"name":"Jiangsu key R&amp;D plan","award":["2023YFF0723400"],"award-info":[{"award-number":["2023YFF0723400"]}]},{"name":"Jiangsu key R&amp;D plan","award":["BM2019004"],"award-info":[{"award-number":["BM2019004"]}]},{"name":"National Key R&amp;D Program of China","award":["2017ZX0931057"],"award-info":[{"award-number":["2017ZX0931057"]}]},{"name":"National Key R&amp;D Program of China","award":["BE2019738"],"award-info":[{"award-number":["BE2019738"]}]},{"name":"National Key R&amp;D Program of China","award":["2023YFF0723400"],"award-info":[{"award-number":["2023YFF0723400"]}]},{"name":"National Key R&amp;D Program of China","award":["BM2019004"],"award-info":[{"award-number":["BM2019004"]}]},{"name":"Jiangsu Key Laboratory of Central Nervous System Drug Research and Development","award":["2017ZX0931057"],"award-info":[{"award-number":["2017ZX0931057"]}]},{"name":"Jiangsu Key Laboratory of Central Nervous System Drug Research and Development","award":["BE2019738"],"award-info":[{"award-number":["BE2019738"]}]},{"name":"Jiangsu Key Laboratory of Central Nervous System Drug Research and Development","award":["2023YFF0723400"],"award-info":[{"award-number":["2023YFF0723400"]}]},{"name":"Jiangsu Key Laboratory of Central Nervous System Drug Research and Development","award":["BM2019004"],"award-info":[{"award-number":["BM2019004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>In this research, a variety of novel amphetamine derivatives were synthesized and assessed for their potential as multifaceted antidepressant agents. Among these compounds, compound 11b demonstrated potent inhibitory effects on both serotonin and noradrenaline transporters (SERT\/NET) and high affinity for histamine H3 receptor (H3R), and displayed low affinity for off-target receptors (H1, \u03b11) and hERG channels, which can reduce the prolongation of the QT interval. Molecular docking studies offered a rational binding model of compound 11b when it forms a complex with SERT, NET, and the histamine H3 receptor. In vivo behavioral studies, compound 11b dose-dependently reduced the immobility duration in the mouse FST and TST assays without a stimulatory effect on the locomotor activity. Furthermore, compound 11b had a favorable pharmacokinetic profile in rats. Thus, compound 11b has the potential to develop a novel class of drugs for the treatment of depression.<\/jats:p>","DOI":"10.3390\/molecules29225240","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:03:24Z","timestamp":1730865804000},"page":"5240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT\/NET\/H3 Agents: Synthesis and Biological Evaluation"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7662-6319","authenticated-orcid":false,"given":"Quxiang","family":"Li","sequence":"first","affiliation":[{"name":"School of Pharmacy, Nanjing Tech University, 30th South Puzhu Road, Nanjing 211816, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-9625","authenticated-orcid":false,"given":"Lili","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Nanjing Tech University, 30th South Puzhu Road, Nanjing 211816, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-6218","authenticated-orcid":false,"given":"Dongli","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Central Nervous System Drug Research and Development, Institute of Pharmaceutical Research, Jiangsu Nhwa Pharmaceutical Co., Ltd., Xuzhou 221116, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5669-9510","authenticated-orcid":false,"given":"Junyong","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Nanjing Tech University, 30th South Puzhu Road, Nanjing 211816, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9083-1987","authenticated-orcid":false,"given":"Changda","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Central Nervous System Drug Research and Development, Institute of Pharmaceutical Research, Jiangsu Nhwa Pharmaceutical Co., Ltd., Xuzhou 221116, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3312-0343","authenticated-orcid":false,"given":"Jian","family":"Feng","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Central Nervous System Drug Research and Development, Institute of Pharmaceutical Research, Jiangsu Nhwa Pharmaceutical Co., Ltd., Xuzhou 221116, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0584-9141","authenticated-orcid":false,"given":"Yufan","family":"Qiu","sequence":"additional","affiliation":[{"name":"Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-0824","authenticated-orcid":false,"given":"Xiangqing","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Central Nervous System Drug Research and Development, Institute of Pharmaceutical Research, Jiangsu Nhwa Pharmaceutical Co., Ltd., Xuzhou 221116, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoguang","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Nanjing Tech University, 30th South Puzhu Road, Nanjing 211816, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","article-title":"Novel and emerging treatments for major depression","volume":"401","author":"Marwaha","year":"2023","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Meng, P., Li, C., Duan, S., Ji, S., Xu, Y., Mao, Y., Wang, H., and Tian, J. (2022). Epigenetic Mechanism of 5-HT\/NE\/DA Triple Reuptake Inhibitor on Adult Depression Susceptibility in Early Stress. Mice. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.848251"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852921000791","article-title":"Novel antidepressant drugs: Beyond monoamine targets","volume":"28","author":"Gonda","year":"2023","journal-title":"CNS Spectr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.bmcl.2007.03.034","article-title":"Synthesis and biological evaluation of diamine-based histamine H3 antagonists with serotonin reuptake inhibitor activity","volume":"17","author":"Stocking","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl] piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Ruhland","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.1016\/j.bmcl.2010.09.081","article-title":"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant","volume":"20","author":"Kim","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1021\/acs.jmedchem.6b01827","article-title":"Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges","volume":"61","author":"Subbaiah","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2174\/1570159X19666211102154311","article-title":"Design Strategies, Chemistry and Therapeutic Insights of Multi-target Directed Ligands as Antidepressant Agents","volume":"20","author":"Singh","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.drudis.2020.07.004","article-title":"Recent advances in multi-target directed ligands targeting G-protein-coupled receptors","volume":"25","author":"Ma","year":"2020","journal-title":"Drug Discov. Today."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1517\/14656566.2012.721776","article-title":"Evidence for the use of vilazodone in the treatment of major depressive disorder","volume":"13","author":"Reinhold","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/NDT.S39544","article-title":"New generation multi-modal antidepressants: Focus on vortioxetine for major depressive disorder","volume":"10","author":"Katona","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/jpet.115.230771","article-title":"Histamine H3 receptor regulates sensorimotor gating and dopaminergic signaling in the striatum","volume":"357","author":"Kononoff","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/13543776.2014.848197","article-title":"New developments around histamine H3 receptor antagonists\/inverse agonists: A patent review (2010\u2013present)","volume":"24","year":"2014","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1038\/s41467-022-33880-y","article-title":"Structural basis for recognition of antihistamine drug by human histamine receptor","volume":"13","author":"Peng","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Qian, H., Shu, C., Xiao, L., and Wang, G. (2022). Histamine and histamine receptors: Roles in major depressive disorder. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.825591"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1016\/j.bmcl.2013.09.081","article-title":"Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3\u2019S)-2-methyl-[1,3\u2019]bipyrrolidinyl-1\u2019-yl)phenyl] amide as histamine H3 receptor antagonist for the treatment of depression","volume":"23","author":"Gao","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2007.08.009","article-title":"Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and serotonin reuptake inhibitor","volume":"576","author":"Barbier","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bmcl.2007.11.016","article-title":"Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors","volume":"18","author":"Ly","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bmcl.2006.11.036","article-title":"Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors","volume":"17","author":"Letavic","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.118.248351","article-title":"Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression","volume":"365","author":"Xu","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14656566.2020.1817387","article-title":"Evaluating pitolisant as a narcolepsy treatment option","volume":"22","author":"Pellitteri","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/11631990-000000000-00000","article-title":"Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder","volume":"26","author":"Weisler","year":"2012","journal-title":"CNS Drugs."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.03.008","article-title":"In vivo pharmacological profile of S 38093, a novel histamine H3 receptor inverse agonist","volume":"803","author":"Panayi","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"891","DOI":"10.4088\/JCP.11m07178","article-title":"Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit\/hyperactivity disorder","volume":"73","author":"Herring","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.111.186585","article-title":"CEP-26401 (irdabisant), a potent and selective histamine H\u2083 receptor antagonist\/inverse agonist with cognition-enhancing and wake-promoting activities","volume":"340","author":"Raddatz","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/oby.22969","article-title":"Antidepressant Medications and Weight Change: A Narrative Review","volume":"28","author":"Gill","year":"2020","journal-title":"Obesity"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Calvi, A., Fischetti, I., Verzicco, I., Belvidere Murri, M., Zanetidou, S., Volpi, R., Coghi, P., Tedeschi, S., Amore, M., and Cabassi, A. (2021). Antidepressant Drugs Effects on Blood Pressure. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.704281"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1017\/S1092852900017089","article-title":"Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines","volume":"13","author":"Stahl","year":"2008","journal-title":"CNS Spectr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5114\/aoms.2019.86928","article-title":"Effects of antidepressants on QT interval in people with mental disorders","volume":"16","author":"Aronow","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1152\/ajpregu.00427.2012","article-title":"Initial orthostatic hypotension and cerebral blood flow regulation: Effect of \u03b11-adrenoreceptor activity","volume":"304","author":"Lewis","year":"2013","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/138945013804806460","article-title":"Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design","volume":"14","author":"Moorthy","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"ref_33","unstructured":"(2024, November 03). Center for Drug Evaluation and Research Approval Package for: Application Number 21-427. Pharmacology Review(s) #3, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/021427_s000_Cymbalta_Pharmr_P2.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-004-2048-7","article-title":"Forced swimming test in mice: A review of antidepressant activity","volume":"177","author":"Chenu","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nature17629","article-title":"X-ray structures and mechanism of the human serotonin transporter","volume":"532","author":"Coleman","year":"2016","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-024-07810-5","article-title":"Substrate binding and inhibition mechanism of norepinephrine transporter","volume":"633","author":"Ji","year":"2024","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"112709","DOI":"10.1016\/j.ejmech.2020.112709","article-title":"Isoquinolinone derivatives as potent CNS multi-receptor D2\/5-HT1A\/5-HT2A\/5-HT6\/5-HT7 agents: Synthesis and pharmacological evaluation","volume":"207","author":"Jin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2012.03.048","article-title":"Pharmacological characterization of A-960656, a histamine H3 receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain","volume":"684","author":"Marlon","year":"2012","journal-title":"Eur. J. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/jm901818u","article-title":"1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0] hexanes: A New Series of Potent and Selective Triple Reuptake Inhibitors","volume":"53","author":"Fabrizio","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ejmech.2009.11.023","article-title":"Efficient microwave combinatorial synthesis of novel indolic arylpiperazine derivatives as serotoninergic ligands","volume":"45","author":"Frecentese","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1021\/acs.jmedchem.8b01096","article-title":"Synthesis and biological evaluation of fused tricyclic heterocycle piperazine (piperidine) derivatives as potential Multireceptor atypical Antipsychotics","volume":"61","author":"Cao","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1016\/j.bmc.2015.01.012","article-title":"Dimeric carbamoylguanidine-type histamine H2 receptor ligands: A new class of potent and selective agonists","volume":"23","author":"Kagermeier","year":"2015","journal-title":"Bioorg Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0165-5728(99)00119-8","article-title":"Radioligand binding assay of M1-M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes","volume":"99","author":"Tayebatim","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ejmech.2016.09.008","article-title":"Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics","volume":"124","author":"Cao","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/jm0503493","article-title":"Synthesis of Thieno[2,3-b]Pyridinones Acting as Cytoprotectants and as Inhibitors of [3H]Glycine Binding to the N-Methyl-D-aspartate (NMDA) Receptor","volume":"49","author":"Buchstaller","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0272-0590(85)90059-4","article-title":"An up-and-down procedure for acute toxicity testing","volume":"5","author":"Bruce","year":"1985","journal-title":"Fundam. Appl. Toxicol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/22\/5240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:27:08Z","timestamp":1760113628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/22\/5240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":48,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["molecules29225240"],"URL":"https:\/\/doi.org\/10.3390\/molecules29225240","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]}}}